Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of GH21 + D-1553 in KRAS G12C-mutant advanced or metastatic solid tumors
CTR20242406Phase 2Active
- Sponsor
- Genhouse Bio
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GH21, garsorasib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), sponsored by Genhouse Bio. Started Jul 2024; status: active.
02
Drugs
GH21garsorasib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20242406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242406.